Table 2.
MIC range, MIC50 and MIC90 of the 48 clinical Aspergillus isolates
| MIC (mg/l) | |||||
|---|---|---|---|---|---|
| Species | Antifungal agent | Range | MIC 50 | MIC 90 | % > ECV f |
| A. niger (n = 17) | AMB a | 0.04–1.5 | 0.44 | 0.75 | 0 |
| ITR b | 0.38–2 | 0.98 | 2 | 0 | |
| VOR c | 0.05–0.12 | 0.1 | 0.13 | 0 | |
| POS d | 0.05–0.25 | 0.12 | 0.25 | 0 | |
| CS e | 0.008–0.12 | 0.03 | 0.07 | 0 | |
| A. flavus (n = 18) | AMB | 0.5–0.32 | 6 | 20.8 | 66.6 |
| ITR | 0.25–1 | 0.5 | 0.83 | 0 | |
| VOR | 0.06–0.5 | 0.19 | 0.25 | 0 | |
| POS | 0.06–0.25 | 0.19 | 0.25 | 0 | |
| CS | 0.004–32 | 0.064 | 32 | 22.2 | |
| A. tubingensis (n = 9) | AMB | 0.09–0.5 | 0.24 | 0.4 | 0 |
| ITR | 0.25–8 | 0.19 | 4.8 | 22.2 | |
| VOR | 0.064–0.38 | 0.13 | 0.38 | 0 | |
| POS | 0.047–0.25 | 0.12 | 0.25 | 0 | |
| CS | 0.008–0.012 | 0.01 | 0.012 | 0 | |
| A. fumigatus (n = 2) | AMB | 3–6 | NRg | NR | NR |
| ITR | 0.8–0.5 | NR | NR | NR | |
| VOR | 0.06–0.13 | NR | NR | NR | |
| POS | 0.06–0.13 | NR | NR | NR | |
| CS | 0.06–0.06 | 0.064 | NR | NR | |
| Aspergillus section Circumdati (n = 2) | AMB | 3–24 | NR | NR | NR |
| ITR | 0.38–1 | NR | NR | NR | |
| VOR | 0.04–0.06 | NR | NR | NR | |
| POS | 0.09–0.25 | NR | NR | NR | |
| CS | 0.023–0.13 | NR | NR | NR | |
| All species (n = 48) | AMB | 0.04–32 | 0.63 | 13.2 | 25 |
| ITR | 0.25–8 | 0.5 | 2 | 4.1 | |
| VOR | 0.04–0.5 | 0.13 | 0.25 | 0 | |
| POS | 0.05–0.25 | 0.13 | 0.25 | 0 | |
| CS | 0.004–32 | 0.023 | 0.125 | 8.3 | |
aamphotericin; bitraconazole; cvoriconazole; dposaconazole; ecaspofungin; fepidemiologic cut-off value; gnot relevant.